Voiding dysfunction
Conditions
Interventions
Study drug group (Odd-numbered group): A 12-week administration of Silodosin 2 mg twice daily
Study drug group(Even-numbered group): A 8-week administration of Silodosin 4 mg twice daily after a
Sponsors
Dokkyo Medical University
Eligibility
Sex/Gender
Female
Inclusion criteria
Inclusion criteria: 1)over 50ml residual urine volume or 2)over 2 points I-PSS and 3)patinets who can answer the questionnaire 4)out-patient 5)Patients who agree to contraception use
Exclusion criteria
Exclusion criteria: 1)severe heart disease 2)severe liver diseae or over 3mg/dl total bilirubin or over 2.5 times AST(GOT)o ALT(GPT) 3)severe kidney disease or over 1.5mg/dl creatinine 4)severe hypotention 5)women who are pregnant, breast-feeding, or seeking to conceive or may conceive due to improper contraception method during the study period 6)Patients receiving surgical therapy, which may influence the lower urinary tract function 7)Patients receiving nonpharmacologic therapy within 4 weeks prior to the study commencement, which may influence the lower urinary tract function 8)Patients who received an investigational drug in other clinical study within 1 month prior to the study commencement (the period of which should be calculated based on the date on which the investigational drug was administered) 9)Patients who are otherwise ineligible to take part in the study as judged by Principal Investigator or other relevant person
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Score based on I-PSS | — |
Countries
Japan
Contacts
Public ContactTomoyuki Uchiyama
Dokkyo Medical University Neurourology and Continence Center
Outcome results
None listed